NCT00690235View on ClinicalTrials.gov

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
SchizophreniaSchizoaffective DisorderDiabetesWeight Gain
Interventions
DRUG

Pramlintide

180mg subcutaneous injections, twice daily

DRUG

Placebo

180mg subcutaneous injections, twice daily

Trial Locations (1)

75390

The University of Texas Southwestern Medical Center, Dallas

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER